China Resources Double Crane: The wholly-owned subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. received the approval notice for the supplement to the drug application for Dienogest tablets

China Resources Double-Crane announces that its wholly-owned subsidiary, China Resources Zizhu Pharmaceutical Co., Ltd., recently received the “Drug Supplement Application Approval Notice” for Dienogest Tablets issued by the National Medical Products Administration. The medication is used to treat endometriosis, with a total R&D investment of 10.3491 million yuan. In 2025, the company’s sales revenue from this drug is projected to be 35.81 million yuan.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin